On 4 December, our partner Aridhia announced that its digital research platform AnalytiXagility used in the health, biomedical research and precision medicine sectors, is to move all its work to Azure, including treatment studies by the European Prevention of Alzheimer’s Dementia Consortium (EPAD).

Aridhia will use Microsoft’s service to offer medical experts, such as those at EPAD, a secure, efficient and safe way of sharing data to improve patient outcomes, accelerate clinical research and contribute to the development of new drugs.

“We have created a safe space for researchers to work with highly privileged data associated with patients across all types of conditions,” said David Sibbald, Chief Executive of Aridhia. “It allows research groups to work and collaborate with other medical centres across the world, as well as bring in bio-pharmaceutical companies, in a secure environment.

Aridhia is planning to give some customers early access to their Digital Research Platform running on Azure in January.

Check out the joint release between Aridhia and Microsoft here.

Want to find our more? Rodrigo Barnes, Chief Technology Officer at Aridhia, wrote an insightful blog on the Aridhia website.